Faricimab + Ranibizumab

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Choroidal Neovascularization Secondary to Pathologic Myopia

Conditions

Choroidal Neovascularization Secondary to Pathologic Myopia

Trial Timeline

Mar 6, 2024 → May 29, 2026

NCT ID

NCT06176352

About Faricimab + Ranibizumab

Faricimab + Ranibizumab is a phase 3 stage product being developed by Roche for Choroidal Neovascularization Secondary to Pathologic Myopia. The current trial status is active. This product is registered under clinical trial identifier NCT06176352. Target conditions include Choroidal Neovascularization Secondary to Pathologic Myopia.

What happened to similar drugs?

7 of 15 similar drugs in Choroidal Neovascularization Secondary to Pathologic Myopia were approved

Approved (7) Terminated (0) Active (8)

✅Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved

✅ranibizumabNovartisApproved

✅RanibizumabNovartisApproved

✅Intravitreal aflibercept injection 2.0mgRegeneron PharmaceuticalsApproved

✅Rescue Intravitreal Aflibercept InjectionRegeneron PharmaceuticalsApproved

✅Aflibercept Intravitreous InjectionBayerApproved

✅afliberceptBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06176352	Phase 3	Active	Mar 6, 2024	May 29, 2026	Choroidal Neovascularization Secondary to Pathologic Myopia
NCT02699450	Phase 2	Completed	Apr 27, 2016	Dec 14, 2017	Diabetic Macular Edema

Competing Products

20 competing products in Choroidal Neovascularization Secondary to Pathologic Myopia

See all competitors

Product	Company	Stage	Hype Score
Zimura + Eylea	Astellas Pharma	Phase 2	27
Avacincaptad Pegol	Astellas Pharma	Phase 2	35
Verteporfin Photodynamic Therapy + Ranibizumab	Novartis	Approved	43
ranibizumab	Novartis	Approved	43
Ranibizumab	Novartis	Approved	43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT	Novartis	Phase 3	40
ranibizumab	Novartis	Phase 3	40
Everolimus + Ranibizumab	Novartis	Phase 2	27
Ranibizumab	Novartis	Phase 3	40
ranibizumab 0.5mg	Novartis	Phase 2	35
ranibizumab	Novartis	Phase 3	40
Brolucizumab 6mg + Brolucizumab 6mg	Novartis	Phase 3	40
Intravitreal injection ranibizumab	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 3	40
Ranibizumab	Novartis	Phase 1/2	32
Faricimab + Ranibizumab + Sham Procedure	Roche	Phase 2	35
Faricimab + Ranibizumab + Sham Procedure	Roche	Phase 2	35
Intravitreal Pegaptanib	Pfizer	Pre-clinical	18
Intravitreal aflibercept injection 2.0mg	Regeneron Pharmaceuticals	Approved	43
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Regeneron Pharmaceuticals	Pre-clinical	26